RU2007116098A - Новые ингибиторы гистон-деацетилаз - Google Patents
Новые ингибиторы гистон-деацетилаз Download PDFInfo
- Publication number
- RU2007116098A RU2007116098A RU2007116098/04A RU2007116098A RU2007116098A RU 2007116098 A RU2007116098 A RU 2007116098A RU 2007116098/04 A RU2007116098/04 A RU 2007116098/04A RU 2007116098 A RU2007116098 A RU 2007116098A RU 2007116098 A RU2007116098 A RU 2007116098A
- Authority
- RU
- Russia
- Prior art keywords
- phenyl
- hydroxyacrylamide
- oxopropenyl
- oxo
- hydroxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/333—Radicals substituted by oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/46—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
- C07D295/112—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/40—Radicals substituted by oxygen atoms
- C07D307/46—Doubly bound oxygen atoms, or two oxygen atoms singly bound to the same carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/80—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/22—Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D333/56—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
Claims (20)
1. Соединение формулы (I)
где R3 выбирают из водорода, алоксиалкила;
Ar является необязательно замещенной арильной или гетероарильной группой.
А выбирают из
где R2 выбирают из водорода, алкила, циклоалкила, арила, арилалкила, гетероциклила, гетероциклилалкила, галогена, галоалкила, гидрокси-, гидрокиалкила, алкокси-, галоалкокси-, амино-, аминоалкила, алкиламино-, (тио)карбониламино-, (тио)аминокарбонила, сульфониламино-, аминосульфонила, (тио)ацила, (тио)ацилокси-, (тио)алкоксикарбонила, нитро- и нитрила;
R1 выбирается из следующих структур:
где Y выбирается из О, S, NH, CH2, NOH или NOR5, где R5 представляет собой алкил, имеющий от 1 до 4 атомов углерода.
2. Соединение по п.1, в котором Ar выбирают из фенила, нафтила, пиридила, пиранила, пирролила, тиенила, фуранила, бензофурила, бензотиенила, индолила необязательно замещенных.
3. Соединение по п.1, в котором Ar замещен одной группой или более, выбранной из галогена, гидроксо-, алкила, алкокси-, трифторалкила, трифторалкокси-, диалкиламино-, морфолила, пиперазинила, метоксикарбонила.
4. Соединение по п.1, в котором R1 группа и R3 - содержащая группа, предпочтительно, связываются в пара положении по отношению друг к другу в кольце А.
5. Соединение по п.1, в котором R2 выбирают из водорода, галогена, алкила, алкокси-.
6. Соединение по п.1, в котором R3 представляет собой водород.
8. Соединение по п.7, в котором в формулах (Ia-d) X представляет собой атом углерода, R2 представляет собой водород и Ar выбирают из: фенила, 2-хлорфенила, 3-хлорфенила, 4-хлорфенила, 2-фторфенила, 3-фторфенила, 4-фторфенила, 2-метилфенила, 3-метилфенила, 4-метилфенила,1-нафтила, 5-дигидробензофурила.
9. Соединения по п.1, выбранные из
3-[3-фтор-4-(3-оксо-3-фенилпропенил)фенил]-N-гидроксиакриламид;
3-[3-хлор-4-(3-оксо-3-фенилпропенил)фенил]-N-гидроксиакриламид;
3-[3-хлор-4-(3-оксо-3-о-толилпропенил)фенил]-К-гидроксиакриламид;
3-{3-хлор-4-[3-(2-метоксифенил)-3-оксопропенил]фенил}-N-гидроксиакриламид;
3-{3-хлор-4-[3-(2-фторфенил)-3-оксопропенил]фенил}-N-гидроксиакриламид;
3-{3-хлор-4-[3-(2-хлорфенил)-3-оксопропенил]фенил}-N-гидроксиакриламид;
3-[3-хлор-4-(3-оксо-3-м-толилпропенил)фенил]-N-гидроксиакриламид;
3-{3-хлор-4-[3-(3-метоксифенил)-3-оксопропенил]фенил}-N-гидроксиакриламид;
3-{3-хлор-4-[3-(3-фторфенил)-3-оксопропенил]фенил}-N-гидроксиакриламид;
3-{3-хлор-4-[3-(3-хлорфенил)-3-оксопропенил]фенил}-N-гидроксиакриламид;
3-[3-хлор-4-(3-оксо-3-п-толилпропенил)фенил]-N-гидроксиакриламид;
3-{3-хлор-4-[3-(4-метоксифенил)-3-оксопропенил]фенил}-N-гидроксиакриламид;
3-{3-хлор-4-[3-(4-фторфенил)-3-оксопропенил]фенил}-N-гидроксиакриламид;
3-{3-хлор-4-[3-(4-хлорфенил)-3-оксопропенил]фенил}-N-гидроксиакриламид;
3-[3-хлор-4-(3-оксо-3-тиофен-2-илпропенил)фенил]-N-гидроксиакриламид;
3-[3-фтор-4-(3-оксо-3-о-толилпропенил)фенил]-N-гидроксиакриламид;
3-{3-фтор-4-[3-(2-метоксифенил)-3-оксопропенил]фенил}-N-гидроксиакриламид;
3-{3-фтор-4-[3-(2-фторфенил)-3-оксопропенил]фенил}-N-гидроксиакриламид;
3-{4-[3-(2-хлорфенил)-3-оксопропенил]фенил}-N-гидроксиакриламид;
3-[3-фтор-4-(3-оксо-3-м-толилпропенил)фенил]-N-гидроксиакриламид;
3-{3-фтор-4-[3-(3-метоксифенил)-3-оксопропенил]фенил}-N-гидроксиакриламид;
3-{3-фтор-4-[3-(3-фторфенил)-3-оксопропенил]фенил}-N-гидроксиакриламид;
3-{4-[3-(3-хлорфенил)-3-оксопропенил]фенил}-N-гидроксиакриламид;
3-[3-фтор-4-(3-оксо-3-п-толилпропенил)фенил]-N-гидроксиакриламид;
3-{3-фтор-4-[3-(4-метоксифенил)-3-оксопропенил]фенил}-N-гидроксиакриламид;
3-{3-фтор-4-[3-(4-фторфенил)-3-оксопропенил]фенил}-N-гидроксиакриламид;
3-{4-[3-(4-хлорфенил)-3-оксопропенил]-3-фторфенил}-N-гидроксиакриламид;
3-[3-фтор-4-(3-оксо-3-тиофен-2-илпропенил)фенил]-N-гидроксиакриламид;
3-{3-фтор-4-[3-(4-морфолин-4-ил-фенил)-3-оксопропенил]фенил}-N-гидроксиакриламид;
N-гидрокси-3-{4-[3-(2-метоксифенил)-3-оксопропенил]фенил}-акриламид;
N-гидрокси-3-{4-[3-оксо-3-(2-трифторметилфенил)пропенил]фенил}-акриламид;
N-гидрокси-3-{4-[3-оксо-3-(2-трифторметоксифенил)пропенил]фенил}-акриламид;
3-{4-[3-(2-бромфенил)-3-оксопропенил]фенил}-N-гидроксиакриламид;
N-гидрокси-3-{4-[3-(3-метоксифенил)-3-оксопропенил]фенил}-акриламид;
3-{4-[3-(3-бромфенил)-3-оксопропенил]фенил}-N-гидроксиакриламид;
N-гидрокси-3-{4-[3-(4-метоксифенил)-3-оксопропенил]фенил}акриламид;
N-гидрокси-3-{4-[3-оксо-3-(4-трифторметилфенил)пропенил]фенил}акриламид;
N-гидрокси-3-{4-[3-оксо-3-(4-трифторметоксифенил)пропенил]фенил}-акриламид;
3-{4-[3-(4-бромфенил)-3-оксопропенил]фенил}-N-гидроксиакриламид;
3-{4-[3-(4-диэтиламинфенил)-3-оксопропенил]фенил}-N-гидроксиакриламид;
N-гидрокси-3-{4-[3-4-морфолин-4-ил-фенил)-3-оксопропенил]фенил} акриламид;
3-[4-(3-фуран-2-ил-3-оксопропенил)фенил]-N-гидроксиакриламид;
N-гидрокси-3-[4-(3-оксо-3-тиофен-2-илпропенил)фенил]акриламид;
N-гидрокси-3-{4-[3-оксо3-(1N-пиррол-2-ил)пропенил]фенил}акриламид;
3-[4-(3-бензофуран-2-ил-3-оксопропенил)фенил]-1N-гидроксиакриламид;
3-[4-(3-бензо[b]тиофен-2-ил-3-оксопропенил)фенил]-N-гидроксиакриламид;
N-гидрокси-3-[4-(3-оксо-3-тиофен-3-илпропенил)фенил]акриламид;
N-гидрокси-3-{4-[3-3-метокси-4-морфолин-4-ил-метилфенил)-3-оксопропенил]фенил}акриламид;
3-{4-[3-(3,4-дифторфенил)-3-оксопропенил]-фенил}-N-гидроксиакриламид;
3-{4-[3-(3,5-дифторфенил)-3-оксопропенил]-фенил}-N-гидроксиакриламид;
3-{4-[3-(2,5-дифторфенил)-3-оксопропенил]-фенил}-N-гидроксиакриламид;
3-{4-[3-(2,6-дифторфенил)-3-оксопропенил]-фенил}-N-гидроксиакриламид;
N-гидрокси-3-[3-метокси-4-(3-оксо-3-тиофен-2-ил-пропенил)-фенил]-акриламид;
N-гидрокси-3-[3-метил-4-(3-оксо-3-тиофен-2-ил-пропенил)-фенил]-акриламид;
сложный метиловый эфир 4-{3-[4-(2-гидроксикарбамоилвинил)фенил]-акрилоил}бензойной кислоты;
сложный метиловый эфир 3-{3-[4-(2-гидроксикарбамлоилвинил)-фенил]-акрилоил}бензойной кислоты;
3-{4-[3-(5-хлортиофен-2-ил)-3-оксопропенил]фенил}-N-гидроксиакриламид;
N-гидрокси-3-{4-[3-(3-гидроксифенил)-3-оксопропенил]фенил}акриламид;
N-гидрокси-3-(4-{3-[3-(4-метилпиперазин-1-ил)фенил]-3-оксопропенил} фенил)акриламид;
N-гидрокси-3-[2-метокси-4-(3-oxo-3-фенилпропенил)фенил]-акриламид;
3-[2-фтор-4-(3-оксо-3-фенилпропенил)фенил]-N-гидроксиакриламид;
3-[2-хлор-4-(3-оксо-3-фенилпропенил)фенил]-N-гидроксиакриламид;
N-гидрокси-3-[4-(3-оксо-3-пиридин-3-илпропенил)фенил]акриламид;
N-гидрокси-3-[4-(3-оксо-3-пиридин-2-илпропенил)фенил] акриламид;
N-гидрокси-3-[4-(3-оксо-3-пиридин-4-илпропенил)фенил]акриламид;
N-гидрокси-3-[3-метил-4-(3-охо-3-фенилпропенил)фенил]-акриламид;
N-гидрокси-3-[3-метокси-4-(3-охо-3-фенилпропенил)фенил]-акриламид;
3-[3-фтор-4-(3-оксо-3-пиридин-3-илпропенил)фенил]-N-гидроксиакриламид;
N-гидрокси-3-[5-(3-охо-3-фенилпропенил)пиридин-2-ил]акриламид;
N-гидрокси-3-{5-[3-(2-метоксифенил)-3-оксопропенил]-пиридин-2-ил}акриламид;
N-гидрокси-3-[5-(3-оксо-3-тиофен-2-илпропенил)-пиридин-2-ил]акриламид;
3-{5-[3-(3,4-дифторфенил)-3-оксопропенил]пиридин-2-ил}-N-гидроксиакриламид;
10. Способ получения соединений формулы (I), включающий взаимодействие соединений формулы (II)
где А и R2 имеет вышеприведенные значения и R4 представляет собой подходящую уходящую группу
(i) с соединением формулы Ar-W, где Ar имеет вышеприведенные значения и W представляет собой группу, способную к образованию группы R1 в результате реакции с СНО группой формулы (II) или к синтезу промежуточного соединения,
(ii) и дополнительно с соединением формулы (III)
где Z представляет собой группу NHOR3, как показано выше или ее предшественник.
11. Способ по п.10, где соединение Ar-W представляет собой ацетофенон опционально замещенный фенильным кольцом.
12. Способ по п.10, где реакция присоединения Ar-W происходит в щелочной среде.
13. Способ по п.10, где соединение формулы (III) представляет собой алкилакрилат.
14. Способ по п.10, где соединение формулы (III) представляет собой н-бутилакрилат.
15. Способ по п.11, где реакция присоединения соединения формулы (III) происходит в присутствии фосфата калия и ацетата палладия.
16. Соединение формулы (I) по п.1 для применения в терапии.
17. Фармацевтическая композиция, характеризующиеся включением одного или более активных действующих начал лекарственного вещества формулы (I) по пп.1-9 в сочетании с фармацевтически пригодными наполнителями и разбавителями.
18. Композиция по п.17, пригодная для перорального или парентерального введения в форме таблеток, капсул, препаратов для перорального приема, порошков, гранул, пастилок, регенерируемых порошков, инъекционных или инфузионных жидких растворов или суспензий, суппозиториев, водных или масляных суспензий, растворов, эмульсий, сиропов, эликсиров или в форме, пригодной для трансдермального высвобождения.
19. Соединения по п.17, пригодные для местного применения в виде мази, крема, геля, лосьона, раствора, пасты или т.п., возможно содержащие липосомы, мицеллы и/или микросферы.
20. Применение одного или более соединений формулы (I) по пп.1-9 в приготовлении лекарства для профилактики и/или лечения заболеваний, связанных с разрегуляцией активности гистон-деацетилазы.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITMI2004A001869 | 2004-10-01 | ||
IT001869A ITMI20041869A1 (it) | 2004-10-01 | 2004-10-01 | Nuovi inibitori delle istone deacetilasi |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2007116098A true RU2007116098A (ru) | 2008-11-10 |
RU2416599C2 RU2416599C2 (ru) | 2011-04-20 |
Family
ID=36142302
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2007116098/04A RU2416599C2 (ru) | 2004-10-01 | 2005-09-30 | Новые ингибиторы гистон-деацетилаз |
Country Status (17)
Country | Link |
---|---|
US (2) | US7803800B2 (ru) |
EP (1) | EP1814850B9 (ru) |
JP (1) | JP4979583B2 (ru) |
KR (1) | KR101191558B1 (ru) |
CN (1) | CN101039905B (ru) |
AU (1) | AU2005291297B2 (ru) |
CA (1) | CA2581730C (ru) |
ES (1) | ES2428539T3 (ru) |
HK (1) | HK1110579A1 (ru) |
IL (1) | IL182237A (ru) |
IT (1) | ITMI20041869A1 (ru) |
MX (1) | MX2007003641A (ru) |
NZ (1) | NZ554640A (ru) |
PL (1) | PL1814850T3 (ru) |
RU (1) | RU2416599C2 (ru) |
WO (1) | WO2006037761A1 (ru) |
ZA (1) | ZA200703390B (ru) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITMI20041869A1 (it) | 2004-10-01 | 2005-01-01 | Dac Srl | Nuovi inibitori delle istone deacetilasi |
EP2033956A1 (en) * | 2007-08-28 | 2009-03-11 | DAC S.r.l. | A new class of histone deacetylase inhibitors |
ITMI20060621A1 (it) * | 2006-03-31 | 2007-10-01 | Dac Srl | Nuova classe di inibitori delle istone deacetilasi |
US8242175B2 (en) | 2004-10-01 | 2012-08-14 | Dac S.R.L. | Class of histone deacetylase inhibitors |
WO2008003013A2 (en) * | 2006-06-29 | 2008-01-03 | Abbott Laboratories | Antitumorigenic drug combination comprising an hdac inhibitor and a tsp-1 peptidomimetic |
AU2008266856A1 (en) * | 2007-06-18 | 2008-12-24 | University Of Louisville Research Foundation, Inc. | Family of PFKFB3 inhibitors with anti-neoplastic activities |
CN101255124B (zh) * | 2008-03-26 | 2010-06-02 | 山东大学 | 肉桂酰胺类组蛋白去乙酰化酶抑制剂及其制备方法 |
EP2133334A1 (en) * | 2008-06-09 | 2009-12-16 | DAC S.r.l. | Heterocyclic derivatives as HDAC inhibitors |
US7994357B2 (en) * | 2009-04-03 | 2011-08-09 | Naturewise Biotech & Medicals Corporation | Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase |
CA2839613A1 (en) * | 2011-06-24 | 2012-12-27 | Dow Agrosciences Llc | Pesticidal compositions and processes related thereto |
EP2797875A4 (en) * | 2011-12-29 | 2015-09-02 | Pharmacyclics Inc | CINNAMIC ACID HYDROXYAMIDES AS HISTONE DEACETYLASE INHIBITORS 8 |
WO2013154870A1 (en) | 2012-04-10 | 2013-10-17 | Annji Pharmaceutical Co., Ltd. | Histone deacetylases (hdacs) inhibitors |
CN103102331B (zh) * | 2013-01-17 | 2015-05-27 | 浙江大学 | 含哌嗪环的查尔酮类化合物的药物用途 |
CN103102332B (zh) * | 2013-01-17 | 2015-05-27 | 浙江大学 | 含哌嗪环的查尔酮类化合物及其制备和应用 |
CN103204833A (zh) * | 2013-03-26 | 2013-07-17 | 华东师范大学 | 一种全取代四氢呋喃衍生物的制备方法 |
US10478431B2 (en) | 2014-11-26 | 2019-11-19 | The J. David Gladstone Institutes | Methods for treating a cytomegalovirus infection |
WO2018213364A1 (en) | 2017-05-16 | 2018-11-22 | Annji Pharmaceutical Co., Ltd. | Histone deacetylases (hdacs) inhibitors |
US20220133892A1 (en) * | 2019-02-25 | 2022-05-05 | Emory University | Chimeric Compounds and Methods of Managing Neurological Disorders or Conditions |
US20220154282A1 (en) | 2019-03-12 | 2022-05-19 | The Broad Institute, Inc. | Detection means, compositions and methods for modulating synovial sarcoma cells |
CN115843292A (zh) | 2020-06-08 | 2023-03-24 | 安基生技新药股份有限公司 | 用作选择性hdac6抑制剂的喹唑啉衍生物 |
CN115572244B (zh) * | 2021-06-21 | 2024-04-30 | 复旦大学 | 2’-芳基查尔酮类化合物及其制备方法和在制药中的用途 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995013264A1 (fr) | 1993-11-08 | 1995-05-18 | Terumo Kabushiki Kaisha | Derive d'acide hydroxamique et preparation medicamenteuse contenant ledit derive |
JPH09268125A (ja) * | 1996-04-02 | 1997-10-14 | Terumo Corp | 腎炎治療薬 |
FR2796951A1 (fr) * | 1999-07-26 | 2001-02-02 | Centre Nat Rech Scient | Complexes de phosphine/palladium, utiles comme catalyseurs notamment pour l'arylation d'olefines |
CA2391952C (en) | 1999-11-23 | 2012-01-31 | Methylgene Inc. | Inhibitors of histone deacetylase |
PE20020354A1 (es) * | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
WO2002030879A2 (en) * | 2000-09-29 | 2002-04-18 | Prolifix Limited | Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors |
CA2423868C (en) | 2000-09-29 | 2011-06-07 | Prolifix Limited | Carbamic acid compounds comprising an amide linkage as hdac inhibitors |
WO2003087066A1 (en) | 2002-04-11 | 2003-10-23 | Sk Chemicals, Co., Ltd. | α,β-UNSATURATED HYDROXAMIC ACID DERIVATIVES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS |
US7135493B2 (en) * | 2003-01-13 | 2006-11-14 | Astellas Pharma Inc. | HDAC inhibitor |
EP1682538A4 (en) | 2003-10-27 | 2009-05-27 | S Bio Pte Ltd | BIARYL-ASSOCIATED HYDROXAMATE: PREPARATION AND PHARMACEUTICAL APPLICATIONS |
AR046920A1 (es) | 2003-10-27 | 2006-01-04 | S Bio Pte Ltd | Hidroxamatos conectados a acilurea y conectado a sulfonilurea |
ITMI20041869A1 (it) | 2004-10-01 | 2005-01-01 | Dac Srl | Nuovi inibitori delle istone deacetilasi |
ITMI20060621A1 (it) | 2006-03-31 | 2007-10-01 | Dac Srl | Nuova classe di inibitori delle istone deacetilasi |
-
2004
- 2004-10-01 IT IT001869A patent/ITMI20041869A1/it unknown
-
2005
- 2005-09-30 AU AU2005291297A patent/AU2005291297B2/en not_active Ceased
- 2005-09-30 EP EP05797249.9A patent/EP1814850B9/en not_active Not-in-force
- 2005-09-30 PL PL05797249T patent/PL1814850T3/pl unknown
- 2005-09-30 CA CA2581730A patent/CA2581730C/en not_active Expired - Fee Related
- 2005-09-30 KR KR1020077008870A patent/KR101191558B1/ko not_active IP Right Cessation
- 2005-09-30 NZ NZ554640A patent/NZ554640A/en not_active IP Right Cessation
- 2005-09-30 MX MX2007003641A patent/MX2007003641A/es active IP Right Grant
- 2005-09-30 CN CN2005800354325A patent/CN101039905B/zh not_active Expired - Fee Related
- 2005-09-30 ES ES05797249T patent/ES2428539T3/es active Active
- 2005-09-30 JP JP2007534030A patent/JP4979583B2/ja not_active Expired - Fee Related
- 2005-09-30 RU RU2007116098/04A patent/RU2416599C2/ru not_active IP Right Cessation
- 2005-09-30 US US11/664,187 patent/US7803800B2/en not_active Expired - Fee Related
- 2005-09-30 WO PCT/EP2005/054949 patent/WO2006037761A1/en active Application Filing
-
2007
- 2007-03-27 IL IL182237A patent/IL182237A/en not_active IP Right Cessation
- 2007-04-25 ZA ZA200703390A patent/ZA200703390B/xx unknown
-
2008
- 2008-01-31 HK HK08101191.7A patent/HK1110579A1/xx not_active IP Right Cessation
-
2010
- 2010-06-01 US US12/791,465 patent/US8058273B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
ES2428539T3 (es) | 2013-11-08 |
EP1814850B9 (en) | 2015-02-25 |
WO2006037761A1 (en) | 2006-04-13 |
JP4979583B2 (ja) | 2012-07-18 |
KR20070070179A (ko) | 2007-07-03 |
ZA200703390B (en) | 2008-10-29 |
AU2005291297B2 (en) | 2010-12-23 |
JP2008514682A (ja) | 2008-05-08 |
CN101039905B (zh) | 2012-02-08 |
AU2005291297A1 (en) | 2006-04-13 |
ITMI20041869A1 (it) | 2005-01-01 |
RU2416599C2 (ru) | 2011-04-20 |
US7803800B2 (en) | 2010-09-28 |
NZ554640A (en) | 2009-09-25 |
ES2428539T9 (es) | 2015-09-15 |
CA2581730A1 (en) | 2006-04-13 |
EP1814850A1 (en) | 2007-08-08 |
CN101039905A (zh) | 2007-09-19 |
US20080096889A1 (en) | 2008-04-24 |
PL1814850T3 (pl) | 2013-12-31 |
HK1110579A1 (en) | 2008-07-18 |
IL182237A (en) | 2012-03-29 |
US8058273B2 (en) | 2011-11-15 |
KR101191558B1 (ko) | 2012-10-15 |
IL182237A0 (en) | 2007-09-20 |
MX2007003641A (es) | 2007-08-14 |
EP1814850B1 (en) | 2013-07-03 |
US20100240660A1 (en) | 2010-09-23 |
CA2581730C (en) | 2012-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2007116098A (ru) | Новые ингибиторы гистон-деацетилаз | |
RU2007107189A (ru) | Производные арилпиридина | |
RU2492167C2 (ru) | Производные аминотриазола в качестве агонистов alх | |
RU2408589C2 (ru) | Соединения и композиции в качестве модуляторов ppar-рецепторов, активируемых пролифератором пероксисом | |
RU2001132139A (ru) | Имидазохинолины с сульфонамидными или сульфамидным замещением | |
RU2001132570A (ru) | Мочевинозамещенные имидазохинолины | |
RU2002127781A (ru) | Производные карбоновых кислот в качестве антагонистов ip | |
RU2004119438A (ru) | Производные бензотиазола | |
RU2006129297A (ru) | Производные n-(1,5-дифенил-1н-пиразол-3-ил)сульфонамида со сродством к рецепторам cb1 | |
RU2007140244A (ru) | Произвдное соединение пропан-1,3-диона или его соль | |
RU2011129786A (ru) | Триазолопиридины в качестве ингибиторов фосфодиэстеразы для лечения кожных заболеваний | |
RU2007141892A (ru) | 5-метил-1-(замещенный фенил)-2-(1н)-пиридон для производства медикаментов для лечения фиброза в органах и тканях | |
RU2007124677A (ru) | 3-замещенные производные пиридина в качестве антагонистов гистаминовых h3 рецепторов | |
RU2420522C2 (ru) | Новый класс ингибиторов гистондеацетилаз | |
RU2007116033A (ru) | Производные индазолона в качестве ингибиторов 11b-hsd1 | |
RU2010120682A (ru) | Ингибиторы гистондезацетилазы | |
MX2013005124A (es) | Estimuladores de la gcs. | |
RU2007133602A (ru) | Производные n-[(4,5-дифенил-2-тиенил)метил]амина, их получение и применение в терапии | |
RU2007126761A (ru) | ПРОИЗВОДНЫЕ ПИРРОЛА, ОБЛАДАЮЩИЕ АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К РЕЦЕПТОРУ CRTh2 | |
CA2396824A1 (en) | Heteroaromatic carboxamide derivatives and their use as inhibitors of the enzyme ikk-2 | |
RU2007101685A (ru) | Модуляторы никотиновых ацетилхолиновых рецепторов альфа 7 и их терапевтические применения | |
RU2008116314A (ru) | Соединения карбоксамина и их применение для лечения hdac-зависимых заболеваний | |
RU2012130958A (ru) | Новые фенольные производные и их фармацевтическое или косметическое применение | |
RU2004100302A (ru) | Амиды антраниловой кислоты с гетероарилсульфонильной боковой цепью, способ их получения, их применение в качестве лекарственного или диагностического средства, а также содержащие их фармацевтические композиции | |
RU2015153063A (ru) | Гетероциклические производные и их применение |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20131001 |